Strategies for use of IL-10 or its antagonists in human disease

被引:354
作者
O'Garra, Anne [1 ]
Barrat, Franck J.
Castro, Antonio G. [2 ,3 ]
Vicari, Alain [4 ]
Hawrylowicz, Catherine [5 ,6 ,7 ]
机构
[1] Natl Inst Med Res, MRC, Div Immunoregulat, London NW7 1AA, England
[2] Univ Minho, Sch Hlth Sci, Braga, Portugal
[3] Univ Minho, Life & Hlth Sci Res Inst, Braga, Portugal
[4] Coley Pharmaceut Grp, Kanata, ON, Canada
[5] Kings Coll London, Guys Hosp, Dept Asthma Allergy & Resp Sci, London WC2R 2LS, England
[6] Kings Coll London, MRC, London WC2R 2LS, England
[7] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London WC2R 2LS, England
基金
英国医学研究理事会;
关键词
IL-10; anti-inflammatory; cytokines;
D O I
10.1111/j.1600-065X.2008.00635.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin-10 (IL-10) is a cytokine with broad anti-inflammatory properties by its suppression of both macrophage and dendritic cell function, including antigen-presenting cell function and the production of proinflammatory cytokines. This can result subsequently in the feedback regulation of both T-helper 1 (Th1)-type and Th2-type responses. This review discusses the potential use of IL-10 or agents that induce IL-10 as potential anti-inflammatory therapies in inflammatory diseases. Although IL-10-deficient mice develop colitis in the presence of normal gut flora and clear certain intracellular pathogens more efficiently, this is often accompanied by immunopathology, which can be lethal to the host. This reinforces the anti-inflammatory properties of IL-10, although it should be noted that as discussed below, IL-10 can also promote B-cell and other immune responses under particular settings. A penalty of its role to limit the immune and inflammatory responses to pathogens and prevent damage to the host is that high or dysregulated levels of IL-10 may result in chronic infection. Thus, antagonists of IL-10 show great potential as adjuvants in preventative or therapeutic vaccines against chronic infection or cancer. This article reviews basic published studies on IL-10, which may lead to potential uses of IL-10 or its antagonists in human disease.
引用
收藏
页码:114 / 131
页数:18
相关论文
共 273 条
[51]   INTERLEUKIN-10 AND TRANSFORMING GROWTH-FACTOR-BETA COOPERATE TO INDUCE ANTI-CD40 ACTIVATED NAIVE HUMAN B-CELLS TO SECRETE IMMUNOGLOBULIN-A [J].
DEFRANCE, T ;
VANBERVLIET, B ;
BRIERE, F ;
DURAND, I ;
ROUSSET, F ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (03) :671-682
[52]   Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses [J].
Dercamp, C ;
Chemin, K ;
Caux, C ;
Trinchieri, G ;
Vicari, AP .
CANCER RESEARCH, 2005, 65 (18) :8479-8486
[53]   Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells [J].
Dhodapkar, MV ;
Steinman, RM ;
Krasovsky, J ;
Munz, C ;
Bhardwaj, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (02) :233-238
[54]   A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells [J].
Dillon, S ;
Agrawal, A ;
Van Dyke, T ;
Landreth, G ;
McCauley, L ;
Koh, A ;
Maliszewski, C ;
Akira, S ;
Pulendran, B .
JOURNAL OF IMMUNOLOGY, 2004, 172 (08) :4733-4743
[55]  
DING L, 1993, J IMMUNOL, V151, P1224
[56]  
DING L, 1992, J IMMUNOL, V148, P3133
[57]   Monocyte/macrophage infiltration in tumors: modulators of angiogenesis [J].
Dirkx, Anita E. M. ;
Egbrink, Mirjam G. A. oude ;
Wagstaff, John ;
Griffioen, Arjan W. .
JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 80 (06) :1183-1196
[58]  
Dummer W, 1996, INT J CANCER, V66, P607, DOI 10.1002/(SICI)1097-0215(19960529)66:5<607::AID-IJC4>3.3.CO
[59]  
2-B
[60]   The three Es of cancer immunoediting [J].
Dunn, GP ;
Old, LJ ;
Schreiber, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :329-360